Ann: Acrux Receives FDA Approval - Generic Testosterone Solution, page-52

Yes I am taking up Part F, full offering of 190,000 shares @$0.157.
Undervalued equity with FDA pipeline and low debt.
Revenue generation to cover operational and future FDA costs for the product pipeline will be covered by the Generic Pharmaceutical Pipeline strategy.

In regards to earning good money off your shares in the future, you will be investing in the future FDA product success not so much the generic pipeline.

I also enjoy with the Australian Government the Labor party talking about Capital Gains Tax again.
They always leave out in their Policies "Pooled Development Funds" such as this, which is a different system all together in itself.
So the Political shielding and potential upside to me is very attractive.